IGC Pharma Inc (AMEX: IGC) on Tuesday, plunged -7.62% from the previous trading day, before settling in for the closing price of $0.43. Within the past 52 weeks, IGC’s price has moved between $0.25 and $0.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4.59% annually for the last half of the decade. The company achieved an average annual earnings per share of 45.45%. With a float of $52.02 million, this company’s outstanding shares have now reached $66.69 million.
In an organization with 67 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 33.8%, operating margin of -946.8%, and the pretax margin is -1252.64%.
IGC Pharma Inc (IGC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of IGC Pharma Inc is 31.22%, while institutional ownership is 3.39%. The most recent insider transaction that took place on Aug 12 ’24, was worth 78,200.
IGC Pharma Inc (IGC) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.4 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.04) by -0.36. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.45% per share during the next fiscal year.
IGC Pharma Inc (AMEX: IGC) Trading Performance Indicators
IGC Pharma Inc (IGC) is currently performing well based on its current performance indicators. A quick ratio of 1.15 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of IGC Pharma Inc (IGC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.37 million. That was inferior than the volume of 0.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.75%. Additionally, its Average True Range was 0.03.
During the past 100 days, IGC Pharma Inc’s (IGC) raw stochastic average was set at 2.62%, which indicates a significant decrease from 14.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.67% in the past 14 days, which was lower than the 110.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4344, while its 200-day Moving Average is $0.3901. However, in the short run, IGC Pharma Inc’s stock first resistance to watch stands at $0.4153. Second resistance stands at $0.4365. The third major resistance level sits at $0.4527. If the price goes on to break the first support level at $0.3779, it is likely to go to the next support level at $0.3617. The third support level lies at $0.3405 if the price breaches the second support level.
IGC Pharma Inc (AMEX: IGC) Key Stats
Market capitalization of the company is 29.80 million based on 75,636K outstanding shares. Right now, sales total 1,350 K and income totals -13,000 K. The company made 270 K in profit during its latest quarter, and -2,380 K in sales during its previous quarter.
